Trial reportAnnals of surgical oncology2025
Ninety Days of Preoperative Endocrine Therapy Informs Patient and Physician Preference for Radiation Therapy: Primary Results from the Preoperative Window of Endocrine Therapy to Inform Radiation Therapy Decisions (POWER) Trial.
Trial report in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ASO Author Reflections: Ninety Days of Preoperative Endocrine Therapy Informs Patient and Physician Preference for Radiation Therapy.Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundClinical trial data support the omission of radiation therapy (RT) in older women with early-stage breast cancer. The majority of older women still receive RT largely due to a lack of insight regarding endocrine therapy (ET) tolerance. The POWER trial is a phase II trial designed to determine whether 90 days of preoperative ET (pre-ET) changes patient or surgeon preferences for RT.
methodsBetween 2020 and 2024, two centers enrolled women aged 65 years or older with invasive carcinoma measuring ≤2 cm, N0, and ER+/PR±/HER2-. All participants were recommended for 90 days of pre-ET. Patient and surgeon preferences for RT were evaluated before and after pre-ET. A change in preference was tested from an assumed low change rate of 5% to a rate of ≥15%, with a one-sided 5% level binomial test.
resultsSeventy-five women enrolled. Adverse events attributed to pre-ET occurred in 35 participants (47%). After pre-ET, 21 (28.0%) patients changed RT preference and surgeons changed RT recommendation for 18 (24.0%) patients (p < 0.001 and p = 0.015, respectively). General agreement between patient and surgeon preferences before pre-ET was 53% (Kappa = -0.04) and increased to 81% (Kappa = 0.59) after pre-ET.
conclusionPre-ET significantly changed patient and surgeon preferences for RT and increased patient and surgeon agreement. The intentional resequencing of treatments enables patients to assess tolerance to ET before deciding whether to omit RT. This study validates pre-ET as an innovative method to inform adjuvant therapy decisions and recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.